RxDoctor Payments Data

Sean Cassleman, DO

Internal Medicine · Saint Clair Shores, MINPI 1720404775

Payments from drug & device makers

$927in general payments, 2019–2025

Across 58 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$361
  • Novartis$92
  • Pfizer$87
  • GSK$78
  • Lilly USA, LLC$62
  • AstraZeneca$34
  • plus $214 from 11 others

What the payments were for

  • Food & beverage$927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$927 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$60,963
Medicare patients
158
Services billed
711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$94,257
FarxigaDapagliflozin Propanediol74$83,959
EliquisApixaban60$72,227
TrulicityDulaglutide56$70,610
JardianceEmpagliflozin45$67,623
MounjaroTirzepatide31$37,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$32,679
JanuviaSitagliptin Phosphate18$26,065
XareltoRivaroxaban16$20,780
SymbicortBudesonide/Formoterol Fumarate15$7,254
Incruse ElliptaUmeclidinium Bromide11$5,226
Atorvastatin Calcium410$5,060
Varenicline Tartrate11$4,886
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,862
Albuterol Sulfate HfaAlbuterol Sulfate91$3,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$62$107,90987 claims
Novo NordiskOzempic$361$94,25774 claims
AstraZenecaFarxiga, Symbicort$34$91,21389 claims
PfizerEliquis$87$72,22760 claims
Boehringer IngelheimJardiance$22$67,62345 claims
GSKTrelegy Ellipta, Incruse Ellipta$78$37,90445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Saint Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →